EHA Library - The official digital education library of European Hematology Association (EHA)

THE COMBINATION OF LOW ADAMTS-13 ACTIVITY AND HIGH ANTI-ADAMTS13 ANTIBODIES AT REMISSION HIGHLY PREDICTS DISEASE RELAPSE IN PATIENTS WITH ACQUIRED TTP: A MULTI-INSTITUTIONAL STUDY
Author(s): ,
Francesca Schieppati
Affiliations:
Immunohematology and Transfusion Medicine,ASST Papa Giovanni XXIII,Bergamo,Italy
,
Laura Russo
Affiliations:
Immunohematology and Transfusion Medicine,ASST Papa Giovanni XXIII,Bergamo,Italy
,
Marina Marchetti
Affiliations:
Immunohematology and Transfusion Medicine,ASST Papa Giovanni XXIII,Bergamo,Italy
,
Gloria Caldara
Affiliations:
Immunohematology and Transfusion Medicine,ASST Papa Giovanni XXIII,Bergamo,Italy
,
Shenaz Brevi
Affiliations:
Immunohematology and Transfusion Medicine,ASST Papa Giovanni XXIII,Bergamo,Italy
,
Maria Testa
Affiliations:
Immunohematology and Transfusion Medicine,ASST Papa Giovanni XXIII,Bergamo,Italy
,
Luca Barcella
Affiliations:
Immunohematology and Transfusion Medicine,ASST Papa Giovanni XXIII,Bergamo,Italy
,
Maurizio Cefis
Affiliations:
Immunohematology and Transfusion Medicine,ASST Papa Giovanni XXIII,Bergamo,Italy
,
Monica Carpenedo
Affiliations:
Hematology,Hospital San Gerardo,Monza,Italy
,
Mariella D'Adda
Affiliations:
Hematology,ASST Spedali Civili,Brescia,Italy
,
Giuseppe Rossi
Affiliations:
Hematology,ASST Spedali Civili,Brescia,Italy
,
Chiara Savignano
Affiliations:
Transfusion Medicine,University Hospital,Udine,Italy
,
Atto Billio
Affiliations:
Hematology,Azienda Sanitaria dell'Alto Adige,Bolzano,Italy
,
Massimiliano Bruno Franco
Affiliations:
Immunohematology and Transfusion Medicine,ASL1,Imperia,Italy
,
Vincenzo Toschi
Affiliations:
Immunohematology and Transfusion Medicine,Hospital San Carlo Borromeo,Milano,Italy
Anna Falanga
Affiliations:
Immunohematology and Transfusion Medicine,ASST Papa Giovanni XXIII,Bergamo,Italy;University of Milano-Bicocca,Milano,Italy
EHA Library. Schieppati F. 06/16/19; 267400; S1646
Francesca Schieppati
Francesca Schieppati
Contributions
Abstract

Abstract: S1646

Type: Oral Presentation

Presentation during EHA24: On Sunday, June 16, 2019 from 09:00 - 09:15

Location: Hall E106

Background
Acquired thrombotic thrombocytopenic purpura (aTTP) is an immune-mediated life-threatening thrombotic microangiopathy (TMA). Daily therapeutic plasma exchange (TPE) and the optimized use of rituximab have dramatically improved the overall prognosis, however the rate of disease recurrence remains high. Acute-phase treatment and specific predictors of relapse can be relevant for an optimal patient management.

Aims
In a large multicenter cohort of aTTP patients, we aimed to analyze the effect of acute-phase treatment on disease recurrence and to identify predictive variables of relapse.

Methods
From 2002 to 2018, 325 TMA were referred to our Centers. A complete ADAMTS13 activity deficiency (<10%) was diagnostic for TTP in 163 patients. An anti-ADAMTS13 Ab titer >15U/L was considered positive and identified aTTP cases. Seventy-four aTTP patients with complete medical records were enrolled into the study and prospectively monitored. Complete response (CR) to treatment was defined as platelets >150x109/L for >2 days and LDH normalization, lasting for 30 days; a suboptimal response included exacerbation (EX) = recurrent disease within 30 days after reaching CR; and refractoriness (REF) = no treatment response by day 30.

Results
aTTP patient characteristics at diagnosis are shown in the Table. Sixty-three patients were evaluated for treatment response. Two (3%) early deaths were due to myocardial infarction and diffuse rectal ischemia after 7 and 10 days from diagnosis, respectively. Forty patients (64%) obtained a CR after a median time to response (mTTR) of 10 days and a median number of TPE (mTPE) of 7; 21 (33%) obtained a suboptimal response: 13 EX (mTTR 31 days, mTPE 13), and 8 REF (mTTR 42.5, mTPE 19). Thirteen patients with a suboptimal response to TPE were treated with rituximab, all obtaining CR. TTR to 1st line treatment <13 days significantly correlated with a sustained CR (p = 0.004). At remission, 57% of patients showed normal levels (>50%) of ADAMTS13 activity, while 20% a moderate (21-50%), 10% a severe (10-20%), and 11% a complete (<10%) deficiency. A complete or partial recovery of ADAMTS13 activity was associated to negative Ab levels in 90% of cases. Twenty-one patients (34%) relapsed, 14 of them had multiple relapses. Median follow-up was 7 years. Patients were evaluated for predictive parameters of disease recurrence. By multivariate analysis, the association of ADAMTS13 activity ≤20% with a high anti-ADAMTS-13 titer during remission, and a TTR to 1st line treatment ≥13 days, were independent prognostic factors of relapse (p = 0.003 and p = 0.004, respectively). Furthermore, the use of rituximab in patients with a suboptimal TPE response significantly reduced relapse rate (p = 0.002). By Cox regression analysis, patients with ADAMTS13 activity ≤20% plus anti-ADAMTS13 Ab titer >15U/L at remission had an increased risk of relapse (HR 1.98, CI 95% 1.087-3.614; p < 0.02).

Conclusion

In conclusion, our study shows that the association of a low ADAMTS13 activity with high anti-ADAMTS13 antibodies is highly predictive of disease relapse. Moreover, a shorter time to 1st line CR achievement and the salvage use of rituximab in suboptimal responders to TPE significantly reduces relapse. These observations support the use of new therapeutic strategies able to provide faster responses to 1st line TPE treatment in these patients.

Session topic: 34. Thrombosis and vascular biology - Biology & Translational Research

Keyword(s): ADAMTS13, Relapse, TTP

Abstract: S1646

Type: Oral Presentation

Presentation during EHA24: On Sunday, June 16, 2019 from 09:00 - 09:15

Location: Hall E106

Background
Acquired thrombotic thrombocytopenic purpura (aTTP) is an immune-mediated life-threatening thrombotic microangiopathy (TMA). Daily therapeutic plasma exchange (TPE) and the optimized use of rituximab have dramatically improved the overall prognosis, however the rate of disease recurrence remains high. Acute-phase treatment and specific predictors of relapse can be relevant for an optimal patient management.

Aims
In a large multicenter cohort of aTTP patients, we aimed to analyze the effect of acute-phase treatment on disease recurrence and to identify predictive variables of relapse.

Methods
From 2002 to 2018, 325 TMA were referred to our Centers. A complete ADAMTS13 activity deficiency (<10%) was diagnostic for TTP in 163 patients. An anti-ADAMTS13 Ab titer >15U/L was considered positive and identified aTTP cases. Seventy-four aTTP patients with complete medical records were enrolled into the study and prospectively monitored. Complete response (CR) to treatment was defined as platelets >150x109/L for >2 days and LDH normalization, lasting for 30 days; a suboptimal response included exacerbation (EX) = recurrent disease within 30 days after reaching CR; and refractoriness (REF) = no treatment response by day 30.

Results
aTTP patient characteristics at diagnosis are shown in the Table. Sixty-three patients were evaluated for treatment response. Two (3%) early deaths were due to myocardial infarction and diffuse rectal ischemia after 7 and 10 days from diagnosis, respectively. Forty patients (64%) obtained a CR after a median time to response (mTTR) of 10 days and a median number of TPE (mTPE) of 7; 21 (33%) obtained a suboptimal response: 13 EX (mTTR 31 days, mTPE 13), and 8 REF (mTTR 42.5, mTPE 19). Thirteen patients with a suboptimal response to TPE were treated with rituximab, all obtaining CR. TTR to 1st line treatment <13 days significantly correlated with a sustained CR (p = 0.004). At remission, 57% of patients showed normal levels (>50%) of ADAMTS13 activity, while 20% a moderate (21-50%), 10% a severe (10-20%), and 11% a complete (<10%) deficiency. A complete or partial recovery of ADAMTS13 activity was associated to negative Ab levels in 90% of cases. Twenty-one patients (34%) relapsed, 14 of them had multiple relapses. Median follow-up was 7 years. Patients were evaluated for predictive parameters of disease recurrence. By multivariate analysis, the association of ADAMTS13 activity ≤20% with a high anti-ADAMTS-13 titer during remission, and a TTR to 1st line treatment ≥13 days, were independent prognostic factors of relapse (p = 0.003 and p = 0.004, respectively). Furthermore, the use of rituximab in patients with a suboptimal TPE response significantly reduced relapse rate (p = 0.002). By Cox regression analysis, patients with ADAMTS13 activity ≤20% plus anti-ADAMTS13 Ab titer >15U/L at remission had an increased risk of relapse (HR 1.98, CI 95% 1.087-3.614; p < 0.02).

Conclusion

In conclusion, our study shows that the association of a low ADAMTS13 activity with high anti-ADAMTS13 antibodies is highly predictive of disease relapse. Moreover, a shorter time to 1st line CR achievement and the salvage use of rituximab in suboptimal responders to TPE significantly reduces relapse. These observations support the use of new therapeutic strategies able to provide faster responses to 1st line TPE treatment in these patients.

Session topic: 34. Thrombosis and vascular biology - Biology & Translational Research

Keyword(s): ADAMTS13, Relapse, TTP

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies